Abstract:Alessandra Morano, 1 Martina Fanella, 1 Mariarita Albini, 1 Pierangelo Cifelli, 2, 3 Eleonora Palma, 2 Anna Teresa Giallonardo, 1 Carlo Di Bonaventura 1 1 Epilepsy Unit, Department of Human Neurosciences, "Sapienza" University of Rome, Rome, Italy; 2 Department of Physiology and Pharmacology, Pasteur Institute-Cenci Bolognetti Foundation, University of Rome Sapienza, Rome, Italy; 3 IRCCS "Neuromed", Pozzilli, IS, Italy Correspondence: Carlo Di Bonaventura Epilepsy Unit, Department of Human Neurosciences, "Sapienza" University of Rome, P.le A. Moro, 5, Rome 00185, Italy Email c_dibonaventura@yahoo.it Cannabidiol (CBD) is one of the prominent phytocannabinoids found in Cannabis sativa , differentiating from Δ 9 -tetrahydrocannabinol (THC) for its non-intoxicating profile and its antianxiety/antipsychotic effects. CBD is a multi-target drug whose anti-convulsant properties are supposed to be independent of endocannabinoid receptor CB 1 and might be related to several underlying mechanisms, such as antagonism on the orphan GPR55 receptor, regulation of adenosine tone, activation of 5HT 1A receptors and modulation of calcium intracellular levels. CBD is a lipophilic compound with low oral bioavailability (6%) due to poor intestinal absorption and high first-pass metabolism. Its exposure parameters are greatly influenced by feeding status (ie, high fat-containing meals). It is mainly metabolized by cytochrome P 450 (CYP) 3A4 and 2C19, which it strongly inhibits. A proprietary formulation of highly purified, plant-derived CBD has been recently licensed as an adjunctive treatment for Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), while it is being currently investigated in tuberous sclerosis complex. The regulatory agencies' approval was granted based on four pivotal double-blind, placebo-controlled, randomized clinical trials (RCTs) on overall 154 DS patients and 396 LGS ones, receiving CBD 10 or 20 mg/kg/day BID as active treatment. The primary endpoint (reduction in monthly seizure frequency) was met by both CBD doses. Most patients reported adverse events (AEs), generally from mild to moderate and transient, which mainly consisted of somnolence, sedation, decreased appetite, diarrhea and elevation in aminotransferase levels, the last being documented only in subjects on concomitant valproate therapy. The interaction between CBD and clobazam, likely due to CYP2C19 inhibition, might contribute to some AEs, especially somnolence, but also to CBD clinical effectiveness. Cannabidivarin (CBDV), the propyl analogue of CBD, showed anti-convulsant properties in pre-clinical studies, but a plant-derived, purified proprietary formulation of CBDV recently failed the Phase II RCT in patients with uncontrolled focal seizures. Keywords: cannabidiol, cannabidivarin, phytocannabinoids, epileptic encephalopathies, tuberous sclerosis complex, drug-resistance

Optimization of Seizure Prevention by Cannabidiol (CBD)

Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy

Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy

Cannabidiol Exerts Anticonvulsant Effects Alone and in Combination with Δ9-THC through the 5-HT1A Receptor in the Neocortex of Mice

Decoding epilepsy treatment: A comparative evaluation contrasting cannabidiol pharmacokinetics in adult and paediatric populations

Cannabidiol exerts antiepileptic effects by restoring hippocampal interneuron functions in a temporal lobe epilepsy model

Cannabinoids in the Treatment of Epilepsy: Current Status and Future Prospects

Preclinical safety and efficacy of cannabidivarin for early life seizures

High Dosage of Cannabidiol (cbd) Alleviates Pentylenetetrazole-Induced Epilepsy in Rats by Exerting an Anticonvulsive Effect

The Potential Mechanism of Cannabidiol (CBD) Treatment of Epilepsy in Pentetrazol (PTZ) Kindling Mice Uncovered by Multi-Omics Analysis

Cannabichromene from Full-Spectrum Hemp Extract Exerts Acute Anti-Seizure Effects Through Allosteric Activation of GABAA Receptors

Pharmacological Effects of Cannabinoids Extracted from Industrial hemp on Epilepsy

Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program

Cannabidiol inhibits febrile seizure by modulating AMPA receptor kinetics through its interaction with the N-terminal domain of GluA1/GluA2

A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin As Add-on Therapy in Participants with Inadequately Controlled Focal Seizures

Cannabidiol and brain function: current knowledge and future perspectives

Safety and efficacy of cannabidiol-cannabidiolic acid rich hemp extract in the treatment of refractory epileptic seizures in dogs

Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome

Pharmacological characterization of the cannabinoid receptor 2 agonist, β-caryophyllene on seizure models in mice

CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience

Multi-level therapeutic actions of cannabidiol in ketamine-induced schizophrenia psychopathology in male rats